JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Complete title: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study
Research Study Description
This phase II trial studies how well giving a JAK inhibitor before a donor stem cell transplant works in treating patients with myelofibrosis that developed without another condition (primary) or evolved from other bone marrow disorders (secondary). JAK inhibitors are a class of drugs that may stop the growth of abnormal cells by blocking an enzyme needed for cell growth. Giving a JAK inhibitor before a donor stem cell transplant may help reduce symptoms of myelofibrosis such as inflammation and enlargement of the spleen, improve the patient's general physical condition, and prevent complications from occurring after the transplant. Infusing healthy stem cells from a donor into the patient may help the patient's bone marrow work normally and make stem cells, red blood cells, white blood cells, and platelets. Giving a JAK inhibitor before a donor stem cell transplant may help improve transplant outcomes in patients with myelofibrosis.
Eligibility Criteria (must meet the following to participate in this
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
|Seattle Cancer Care Alliance Intake Office
|800-804-8824 / 206-606-1024
Hematologic Malignancies; Myelodysplastic Syndromes (MDS); Neoplasms; Myeloproliferative Disorders (MPD); Myelofibrosis, Primary; Myelofibrosis, Secondary; Bone Marrow Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.